Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial - Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalInternational Journal of Advances in Rheumatology
Volume8
Issue number3
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Rheumatology

Cite this